36F79724D0020-75H71224A00007
This Blanket Purchase Agreement (BPA) awarded by the Indian Health Service, a civilian federal agency, provides Biomerieux Inc. with a contract vehicle to supply its proprietary BioFire panel reagents and associated diagnostic equipment and services to support the agency's infectious disease testing and pathogen detection needs.
The BPA, valued at up to $11,727,635.40, has a performance period extending to May 2029 and is issued under the General Services Administration's In Vitro Diagnostics, Reagents, Test (FSS-65-VII) schedule. Biomerieux Inc., a global leader in in vitro diagnostics, is the prime contractor and will deliver its BioFire panel reagents, which are used for rapid and accurate pathogen identification. The contract does not utilize any set-aside designations. Task orders issued under the BPA, valued at $69,870.49 and $1,216,476.00 respectively, specify the delivery of BioFire panel reagents to support the Indian Health Service's PAO AREA-WIDE BIOFIRE PANEL REAGENTS program at facilities in Arizona.
Biomerieux Inc.
$11.7m 5/6/24 5/5/29 5/6/24 36F79724D0020-36C26325N0090
The U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 23 (VISN 23), has awarded a Blanket Purchase Agreement (BPA) to Biomerieux Inc., a global leader in in vitro diagnostics, for the delivery of test kit reagents and associated diagnostic platforms. This single-award BPA, with a total ceiling value of $14,732,632.16, is part of Biomerieux's existing Federal Supply Schedule (FSS) contract for In Vitro Diagnostics, Reagents, and Test Kits. The contract, which does not have a set-aside designation, has a period of performance through November 30, 2028 and will support the VA's clinical laboratory operations and healthcare facilities across VISN 23. Biomerieux, through its Biomerieux, Inc. division, will provide a range of its proprietary diagnostic equipment, such as the BioFire FilmArray system and VITEK analyzers, as well as associated reagents and consumables to enable rapid pathogen detection and identification for infectious disease testing.
The task orders issued under this BPA have ceiling values ranging from $42,167.60 to $930,018.60, with firm-fixed-price delivery orders for the supply of test kit reagents to VISN 23 locations. As the sole-source provider for its specialized diagnostic technologies, Biomerieux's products and services are critical in supporting the VA's healthcare operations and ensuring a reliable supply of essential in vitro diagnostic solutions.
Biomerieux Inc.
$14.7m 10/1/24 11/30/28 10/1/24 36F79724D0020-36C26125A0015
This Blanket Purchase Agreement (BPA) is a federal contract Indefinite Delivery Vehicle (IDV) awarded by the Veterans Integrated Service Network 21 (VISN 21) to Biomerieux Inc. through its Biomerieux, Inc. Division. The contract is for a VISN 21-wide Film Array Laboratory Test System, with a ceiling value of $13,000,000 and a period of performance through January 31, 2030.
Biomerieux Inc., a global leader in in vitro diagnostics, will provide its proprietary diagnostic equipment, reagents, and test kits to support infectious disease testing and pathogen detection across VISN 21 healthcare operations. The contract covers a range of Biomerieux's core offerings, including the BioFire FilmArray system, VITEK analyzers, and associated consumables. Biomerieux will also provide maintenance services, technical support, and extended warranties for the supplied equipment. This BPA allows VISN 21 agencies to efficiently access Biomerieux's specialized diagnostic platforms through task orders placed under the contract.
Biomerieux Inc.
$13.0m 2/1/25 1/31/30 1/8/25 36F79724D0020-36C24625A0011
The key elements of this federal contract Indefinite Delivery Vehicle (IDV) award are as follows:
The Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network 6 (VISN 6), awarded a Blanket Purchase Agreement (BPA) to Biomerieux Inc., a global leader in in vitro diagnostics, to provide its proprietary BioFire FilmArray diagnostic systems, associated test kits, and related services. The BPA has a total ceiling value of $6,300,000 and a period of performance through September 30, 2027. The contract is structured as a single award, with no set-aside designation, and allows the VA and potentially other federal agencies to efficiently access Biomerieux's specialized diagnostic platforms and consumables to support their healthcare operations and clinical laboratory testing requirements. The contract includes multiple BPA call orders with firm-fixed-price values ranging from $97,744.04 to $653,933.70 for the delivery of various FilmArray test kits, such as Richmond, Durham, Asheville, Salisbury, Fayetteville, Hampton, and Salem, with ultimate completion dates through September 30, 2025.
Biomerieux Inc., through its Biomerieux, Inc. Division, has extensive experience supplying clinical diagnostic equipment, reagents, and supplies to federal agencies, including the Departments of Veterans Affairs, Defense, Agriculture, and Health and Human Services. The company holds a $194 million Federal Supply Schedule contract for In Vitro Diagnostics, Reagents, and Test Kits, which enables government agencies to access Biomerieux's proprietary diagnostic solutions. This BPA award further strengthens Biomerieux's position as a trusted provider of comprehensive in vitro diagnostic services to support the VA's and other agencies' healthcare and laboratory testing needs.
Biomerieux Inc.
$6.3m 10/1/24 9/30/27 10/1/24 36F79724D0020-36C24425A0002
The Department of Veterans Affairs (VA) has awarded a Blanket Purchase Agreement (BPA) to Biomerieux Inc., a global leader in in vitro diagnostics, for the provision of BIOFIRE MOLECULAR TESTING products and services. The $209,568.78 contract, which has a period of performance through September 30, 2025, is under the VA's Federal Supply Schedule (FSS) contract for In Vitro Diagnostics, Reagents, and Test Kits.
Biomerieux Inc., through its Biomerieux, Inc. division, will supply the VA with its proprietary diagnostic platforms, such as the BioFire FilmArray system, VITEK analyzers, and associated reagents and test kits. This contract supports the VA's healthcare operations and the need for rapid and accurate pathogen detection and identification across its facilities. The contract does not have a set-aside designation, as Biomerieux is often the sole source provider for its specialized technologies.
Biomerieux Inc.
$209.6k 10/1/24 9/30/25 10/1/24